Overview

Dupixent and Narrowband UVB for Atopic Dermatitis

Status:
Not yet recruiting

Trial end date:
2024-03-01

Target enrollment:

Participant gender:

Summary

24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.

Phase:

Phase 4

Details

Lead Sponsor:

Psoriasis Treatment Center of Central New Jersey

Collaborator:

Regeneron Pharmaceuticals